Ovarian Cancer

Why trials studying Ovarian Cancer stopped, in this sample of ClinicalTrials.gov.

42 stopped trials with a clear reason; 86% ended for non-scientific reasons.

Trials

• A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
  NCT07000344 · TERMINATED · futility
  “Results failed to achieve the anticipated effect.”
• A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
  NCT07030907 · TERMINATED · funding business
  “Business decision”
• Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer
  NCT04542603 · WITHDRAWN · funding business
  “No recruitment/enrollment and funding expired.”
• Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
  NCT06714617 · TERMINATED · funding business
  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”
• Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer
  NCT05145569 · WITHDRAWN · logistics pi
  “Per PI and agent sponsor”
• Non-Viral TCR Gene Therapy
  NCT04102436 · WITHDRAWN · manufacturing supply
  “Difficulty with availability of GLP-grade reagents for manufacturing.”
• [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
  NCT05903807 · TERMINATED · slow accrual
  “Early terminated due to low recruitment rate.”
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
  NCT06052852 · TERMINATED · funding business
  “Sponsor decision”
• FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
  NCT05395052 · TERMINATED · funding business
  “This study was terminated by the Sponsor.”
• Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
  NCT05194735 · TERMINATED · funding business
  “Funding”
• A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
  NCT04875806 · TERMINATED · funding business
  “Due to the limited activity in Phase 1, NextCure decided to discontinue development of the anti-B7-H4 antibody monotherapy trial (NC762-01) to move forward with a prioritized B7-H4 ADC program.”
• Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact
  NCT04731441 · TERMINATED · slow accrual
  “Difficulty enrolling and we lost exercise specialist”
• A Study of PY314 in Subjects With Advanced Solid Tumors
  NCT04691375 · TERMINATED · funding business
  “Sponsor business decision.”
• Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
  NCT04586335 · TERMINATED · funding business
  “Business decision”
• Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
  NCT04116320 · TERMINATED · slow accrual
  “Unable to enroll enough patients to complete targeted enrollment in a reasonable time.”
• Optimal Timing of BR55 CEUS of the Ovaries
  NCT04248153 · TERMINATED · funding business
  “Sponsor decision; expiration of available study agent due to long recruitment timeline.”
• A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
  NCT04025216 · TERMINATED · safety
  “The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.”
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
  NCT04234113 · TERMINATED · futility
  “Due to lack of efficacy shown at the time of the interim analysis.”
• Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101
  NCT03644459 · WITHDRAWN · slow accrual
  “Unable to recruit individuals for the study”
• The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors
  NCT03641287 · TERMINATED · funding business
  “Enrollment ended early due to the funding timeline”
• ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
  NCT03287271 · TERMINATED · funding business
  “Due to loss of funding”
• Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
  NCT03189108 · TERMINATED · logistics pi
  “PI left NIH”
• Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
  NCT02933073 · TERMINATED · logistics pi
  “Study recruitment is temporary on hold by the sponsor due to patient recruitment challenges and the ongoing review of the investigational adjuvant.”
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
  NCT02576665 · TERMINATED · funding business
  “Sponsor decision”
• A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
  NCT02452424 · TERMINATED · futility
  “Terminated early for insufficient evidence of clinical efficacy”
• Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer
  NCT01744821 · TERMINATED · slow accrual
  “Inability to recruit study subjects”
• A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
  NCT01685255 · TERMINATED · funding business
  “Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.”
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
  NCT01583686 · TERMINATED · slow accrual
  “Study terminated due to slow/insufficient accrual.”
• Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer
  NCT01017809 · WITHDRAWN · slow accrual
  “NYU 03-67 reached accrual prior to this study opening.”
• The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery
  NCT01284075 · TERMINATED · slow accrual
  “Low accrual”
• Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse
  NCT00926107 · TERMINATED · slow accrual
  “The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment”
• A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
  NCT00637390 · TERMINATED · manufacturing supply
  “Genzyme will no longer supply the study drug for this trial as it does not believe the study will not fully enroll within an appropriate time frame.”
• A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
  NCT00516841 · TERMINATED · futility
  “Decision to terminate recruitment based on lack of efficacy”
• Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
  NCT00748527 · TERMINATED · safety
  “The study was "withdrawn" due to certain adverse events \[hypersensitivity\].”
• Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
  NCT00408070 · TERMINATED · slow accrual
  “Did not meet accrual goals.”
• Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
  NCT00373217 · TERMINATED · slow accrual
  “Slow enrollment rate.”
• Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
  NCT00322881 · TERMINATED · funding business
  “Early closure based on audit by study investigators after 3 patients died on study.”
• Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
  NCT00331422 · TERMINATED · funding business
  “Study was terminated due to lack of available funding.”
• Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer
  NCT00118300 · WITHDRAWN · slow accrual
  “Competing studies”
• Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
  NCT00086632 · TERMINATED · funding business
  “closed by sponser”
• NYU Ovarian Cancer Early Detection Program Blood and Genetics
  NCT00531778 · TERMINATED · funding business
  “insufficient funding and resource”
• Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
  NCT00006262 · TERMINATED · slow accrual
  “Unable to accrue patients to the study.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.